U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}
Concept
Status:
Other

Class:
CONCEPT

Concept
Status:
Possibly Marketed Outside US
Source:
Imdevimab by Regeneron Pharmaceuticals, Inc.
(2020)
Source URL:
First approved in 2020
Source:
Imdevimab by Regeneron Pharmaceuticals, Inc.
Source URL:

Class:
CONCEPT

Concept
Status:
Possibly Marketed Outside US

Class:
CONCEPT

YTTRIUM Y-90 (YTRACIS®, YTTRIGA®) is a radioactive form of the chemical element yttrium. It is used for radiolabelling other medicines. An example of its use is the treatment of some type of tumors, where the radiolabelled medicine carries the radioactivity to the site of a tumor to destroy the tumor cells.
Concept
Status:
Possibly Marketed Outside US
Source:
NCT03151707: Phase 4 Interventional Recruiting Healthy
(2017)
Source URL:

Class:
CONCEPT